Keyword: Ovid Therapeutics
Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.
CEOs weigh in on increasingly large biotech IPOs and an increase in companies going public at earlier stages.
After reporting mixed results earlier this year, Ovid has new trial data for its OV101 drug in Angelman syndrome that it says look a lot stronger.
Ovid Therapeutics has posted a batch of topline data out of its midstage STARS trial in Angelman syndrome as it seeks out a path to approval.
The pair will start three new trials in the third quarter, including a phase 2 pilot study in CDKL5 deficiency disorder and duplication 15q syndrome.
GeneTx will develop an antisense drug for Angelman syndrome, a genetic disorder that affects the nervous system.
Our panel discussed the meaning of good science and how different players can work together to leverage their respective strengths.
We kick off a new long form series assessing the life science industry from its leaders with ex-Teva chief Jeremy Levin.
News that the Trump administration is axing the Obama-era Deferred Action for Childhood Arrivals program has been met with dismay by biotech leaders.
Ovid Therapeutics has hit the bottom of the range in its IPO, resulting in it grossing $75 million.